Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
about
Bisphosphonates for osteoporosis in people with cystic fibrosisBisphosphonates for osteoporosis in people with cystic fibrosisBisphosphonates for osteoporosis in people with cystic fibrosisHypercalcemia of Malignancy: An Update on Pathogenesis and ManagementNovel molecular pathways in Gorham disease: implications for treatmentExposure to bisphosphonates and risk of colorectal cancerDental complications and management of patients on bisphosphonate therapy: A review articleLipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR InvestigationSphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D.Dynamic visualization of RANKL and Th17-mediated osteoclast function.Treatment of multiple myeloma bone disease: experimental and clinical data.Recent advances in bone-targeted therapies of metastatic prostate cancerTetra- to dodecanuclear oxomolybdate complexes with functionalized bisphosphonate ligands: activity in killing tumor cellsHistology of 8 atypical femoral fractures: remodeling but no healingStatins Are Associated With Reduced Mortality in Multiple Myeloma.Farnesyl pyrophosphate is a novel pain-producing molecule via specific activation of TRPV3Bone health and prostate cancer.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulationBisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatmentEwing sarcoma cells express RANKL and support osteoclastogenesis.Lack of correlation between duration of osteonecrosis of the jaw and sequestra tissue morphology: what it tells us about the condition and what it means for future studiesUpdate on denosumab in postmenopausal osteoporosis--recent clinical data.Local delivery of alendronate eluting chitosan scaffold can effectively increase osteoblast functions and inhibit osteoclast differentiation.A systematic review of microsurgical reconstruction of the jaws using vascularized fibula flap technique in patients with bisphosphonate-related osteonecrosisBisphosphonate remains highly localized after elution from porous implantsBisphosphonates for steroid-induced osteoporosis.Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.Bisphosphonates pathway.Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cellsEfficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosisIncreased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.Osteoclast activity modulates B-cell development in the bone marrowComparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.Pluronics-Formulated Farnesol Promotes Efficient Killing and Demonstrates Novel Interactions with Streptococcus mutans Biofilms.Atypical femoral fractures and bisphosphonate use: current evidence and clinical implicationsSurgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.Effect of risedronate on bone in renal transplant recipients.
P2860
Q24197936-9CEE1F1B-7AD3-4552-A49E-A6DDA59C36C8Q24200401-B011C24D-A3C7-4A77-9C70-90AC3FFF96C3Q24239980-C7467A91-DBB1-471C-B094-9AE7F58546FFQ26771719-5E7617C7-A91B-4E49-AE77-8CCD92BB2316Q27005629-9E7F6062-7841-4DF5-B845-070B1396994BQ27022446-E9150029-638A-43C2-89FA-FD7F16B8C2EBQ27022492-51FE19E5-C64C-4E73-961F-D087156BF3DDQ27654261-6A097550-955F-45DB-A262-EA18265D5645Q28288666-92B8E5C8-F6AF-473D-B14B-487715B961E7Q30533914-96F1A97A-CDCA-4AA4-B731-01874712EEB7Q30868833-2E246783-2D57-465E-889C-AE7781845979Q33703763-6CE119C3-AD59-4BCB-A91C-2D1F445D036CQ33722273-C6C830FF-4AF1-490B-A633-791BBE448726Q33774987-F22081BC-7FB2-45B1-A6D3-17292A07E323Q33816591-00AE3C9F-4626-4796-A81D-BA623C3E8032Q33911367-38902825-6805-4059-A5CA-CC177B72889EQ33977536-47A1EC11-50C6-4B88-8F09-2B155A7D1BF7Q34009569-00E9B238-7663-4CAB-9849-2AC2E25825C0Q34023772-D1C38742-B9C7-4299-974F-1771B72E07FEQ34153137-C82E08B1-6BEE-475E-A6A4-2C423B4CBEBEQ34182079-226AA41B-BC31-4BBD-93CC-6CEC7F3CE5CEQ34183161-271B1CC1-C21B-4A20-B049-32739E784A43Q34238507-CA3DCC6B-7C7D-4F2B-B203-E90A9CE81044Q34300462-BC183FDA-C328-4D39-99FE-187ED3CF4439Q34360661-7A2E73E6-4187-4B25-B538-6F9EFECB9A17Q34469883-0D873554-90E2-4F9E-9B5E-96FFF0011EEEQ34477058-96922382-8ABF-415A-864F-D2728F7A9C01Q34542004-5479AFD8-2E2E-431B-8DA3-D2223D07C926Q34645740-8D36745E-61EB-42E2-BAE0-B8E7BDD77634Q34905878-7FE60660-51A3-42CB-B4B4-13DFC9F16058Q34967135-3E376731-2CC3-45DE-8503-B2B6EFAC7919Q35092602-FBF9E12A-4B15-488A-AA17-7C65B070B0ABQ35155516-6F578BE5-FFBB-4609-A8AD-52376DD75863Q35348955-70B0A765-0968-4E1D-98AB-0B480E07632DQ35441390-413A99A6-3EBC-402D-B97E-40014AC11440Q35584866-AE18B105-0A77-487A-BA6F-265B60678E5AQ35723178-8A346C78-5BF0-4D2D-A91C-383F66ABD2C9Q35780856-A92F84DC-FB95-4E52-9637-36E052B63F7DQ35867314-0CA95220-3A3D-4488-8EF4-A2EDA7D46508Q36109164-F60465A7-2B91-4AAE-8349-18796C29B68B
P2860
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Bisphosphonates: an update on ...... e relate to clinical efficacy.
@en
Bisphosphonates: an update on ...... e relate to clinical efficacy.
@nl
type
label
Bisphosphonates: an update on ...... e relate to clinical efficacy.
@en
Bisphosphonates: an update on ...... e relate to clinical efficacy.
@nl
prefLabel
Bisphosphonates: an update on ...... e relate to clinical efficacy.
@en
Bisphosphonates: an update on ...... e relate to clinical efficacy.
@nl
P2093
P356
P1476
Bisphosphonates: an update on ...... e relate to clinical efficacy.
@en
P2093
Aaron Kwaasi
Bobby L Barnett
Frank H Ebetino
Fraser P Coxon
James E Dunford
James T Triffitt
Kathryn L Kavanagh
Mark W Lundy
Michael J Rogers
Nelson B Watts
P304
P356
10.1196/ANNALS.1402.089
P407
P577
2007-11-01T00:00:00Z